|
AFib Wearables’ Psychological Impact | Interactive Plaque
July 22, 2024
|
|
|
|
|
Together with
|
|
|
|
“Despite having strong brains, electrophysiologists adopt new things as if we were emotional shoppers. Our neighbor buys a sports car and we think we need the same car.”
|
|
John M. Mandrola, MD on the “soft thinking” driving pulsed field ablation’s EP buzz.
|
|
|
|
AFib patients are increasingly using consumer wearable devices for symptom monitoring, but a new JAHA study suggests that these devices’ often-publicized healthcare benefits are offset by their negative impacts on patient anxiety and healthcare overuse.
The researchers analyzed 9-month EHR records of 172 propensity‐matched patients with AFib (avg. age: 72), including 83 who used wearable devices (mainly Apple Watch or Fitbit), finding that wearable users…
- Consistently tracked their biometrics, including 45% who checked their heart rate or ECG daily, versus 19% who only checked in response to cardiac symptoms.
- Reported high rates of “intense fear and anxiety” (20% of users) or “always feeling anxious, scared, or concerned” (15% of users).
- Commonly contacted their doctor after receiving a “possible AF” notification, including 20% who “always” notified their doc.
- Were far more concerned about the efficacy of their AF treatments (QoL treatment concern scores: 77.71 vs. 84.11)
As a result, the wearable patients used far more AF-specific health care resources (mean uses: 4.05 vs. 2.7), including more outpatient clinic visits (2.04 vs. 1.33) and more rhythm‐related diagnostic tests and procedures (1.84 vs. 1.00) over the 9 months.
- That includes ECGs (P=0.003), echo exams (P=0.04), and ablation procedures (P=0.03).
The wearable users were also significantly more likely to use informal health care resources such as portals and messaging (5.52 vs. 3.90), sending far more messages to providers (3.59 vs. 2.41) and receiving twice as many responses.
Some might be tempted to chalk this up to the attributes of people who choose to use wearables, but the two groups didn’t differ in education, socioeconomics, AF status/history, or psychiatric status/history.
- In other words, it could be that merely using a wearable is more likely to make AF patients anxious about their conditions, preoccupied with their device metrics, and more likely to seek and receive care.
The Takeaway
Whether clinicians like it or not, wearables are playing a growing role in their patients lives, sometimes helping with early detection, while apparently risking their psychological wellbeing and driving more healthcare use.
As a result, clinicians will likely have to build their expertise in directing care for wearable-detected AFib abnormalities, and helping their patients deal with the psychological aspects of having all this information literally within arms reach.
|
|
|
Track Your Post-Treatment Plaque
Tune-in to this upcoming Cleerly webinar where preventative cardiologist John Osborne, MD, PhD, FACC, FNLA will explore how to use CTA to track plaque progression and identify residual risk post-treatment.
|
|
Experience the Future of Learning: Medtronic Academy 2.0 is Here!
Unlock your ultimate destination for structural heart medical education with the newly redesigned Medtronic Academy 2.0. Gain access to expert-led courses, webinars, and a wealth of resources to stay ahead in cardiovascular care. Visit now!
|
|
The Behavioral Science Behind Optum’s Hemo System
When Optum set out to design its next-generation Cardiology Hemodynamics monitoring system, it put behavior science at the heart of its product strategy. See how Optum’s UX designers applied its behavioral science team’s findings to improve its Hemodynamics solution to help make physicians and technicians even more efficient and user-centric.
|
|
- HeartFlow Plaque, Interactive and Integrated: HeartFlow’s SCCT 2024 presence was highlighted by a major upgrade to its HeartFlow Plaque Analysis platform, adding new interactive visualization features and direct integration with lesion specific FFRCT values. First launched in 2022, HeartFlow Plaque Analysis uses AI to analyze CCTAs, creating a 3D model that quantifies and characterizes plaque volume in the coronary arteries. The new FFRCT-integrated generation now provides insights into both quantified plaque and physiology for a “fully integrated view of a patient’s true burden of coronary artery disease.”
- Costly ATTR-CM Treatments: A new ICER draft report suggests that ATTR-CM treatments fall way short of cost effectiveness benchmarks. The study placed the greatest scrutiny on Pfizer’s tafamidis (aka Vyndaqel and Vyndamax), which is the only currently available ATTR-CM treatment, and would apparently need a 97% lower price in order to meet the $100k per added Quality of Life Year threshold — theoretically reducing its annual net price from $194k to $5,200. Tafamidis’ value challenges are partially because ATTR-CM patients are now being detected and treated earlier.
- Conservative PREVENTion of ASCVD: A study analyzing data from 1,703 adults with stage 1 hypertension found that the PREVENT equations estimate 10-year ASCVD risks far more conservatively than the Pooled Cohort Equations (PCEs). Among these patients, the average ASCVD risk was 5.4% using PCEs and only 2.9% with PREVENT, while more participants had ≥10% risk using the PCEs than with PREVENT (12.5% vs. <10%). These results support another recent study that suggested PREVENT was far more likely to estimate high ASCVD risks than PCE.
- Heartbeat Health Series C: Virtual cardiology practice Heartbeat Health scored $25M in Series C funding (total funding now >$52M) that it will use to add to its clinical offering and care team, and expand to more U.S. customers. Heartbeat Health combines a team of cardiovascular clinicians and digital tools to support a range of virtual care and diagnostic cardiovascular services.
- Lipoprotein(a) Speeds Aortic Stenosis: A systematic review and meta-analysis of five longitudinal studies in Canada and the UK found a strong association between lipoprotein(a) levels and hemodynamic progression of aortic stenosis. In the analysis of a total of 710 patients treated between 2001 and 2023, participants in the top third of LP(a) levels had 41% faster progression of peak aortic jet velocity and 57% faster progression of mean transvalvular gradient than those in the bottom third.
- Lower-Dose Savaysa Effective, Safer: The door is opening wider for treating ≥80-year-old AFib patients with a lower dose of the anticoagulant edoxaban (Daiichi Sankyo’s Savaysa) for stroke prevention. In a post hoc analysis of 1,138 ENGAGE-AF TIMI 48 trial patients, those taking a higher daily dose of 60 mg had 57% more major bleeding events than those taking 30 mg doses, but stroke and embolism rates were similar in the two groups.
- Materialise Acquires FEops: Major 3D technology company Materialise expanded its cardiovascular imaging capabilities with the acquisition of structural heart simulation startup FEops. The acquisition will allow Materialise to combine its Mimics Planner for Structural Heart Interventions solution (creates 3D models for segmentation and anatomical analysis) with FEops’ predictive simulation technology. This combination of anatomy-based 3D planning and AI-based simulation could improve interventionalists’ ability to predict how transcatheter structural heart devices will interact with a patient’s anatomy, allowing more personalized care decisions.
- CCTA Details LP(a)’s Plaque Risk: A new JAMA paper used CCTA to reveal the link between high Lp(a) levels and the progression of high-risk plaques. The researchers performed CCTA scans with Cleerly AI analysis on 267 patients at baseline and after a median of 10 years, finding that those with Lp(a) levels of 125 nmol/L or higher had more atheroma volume (6.9% vs. 3%), while every doubling of Lp(a) increased their odds of having low-density plaque (OR=1.21). Patients with higher Lp(a) levels also had increased pericoronary adipose tissue inflammation.
- Fellow’s Industry Payments: A review of Open Payments disclosures found that 73% of 5,553 cardiologists received non-research general payments from pharmaceutical and medical device manufacturers during the year before graduating (e.g. meal and transportation reimbursements). Cardiology fellows in procedural intensive subspecialties were more likely to get paid (80%, $1,801 median), compared to their nonprocedural colleagues (67%, $198 median).
- Intensive Titration with STRONG Results: Data from the STRONG-HF trial found that intensive uptitration of common heart failure drugs significantly improves decongestion in acute heart failure patients. At 90 days, 75% of patients in the high-intensity care (HIC) group achieved successful decongestion, compared to 68% in the usual care (UC) group. The approach also led to greater weight reduction and lower orthopnea severity. Sustained decongestion in the HIC group was also linked to a 60% lower risk of heart failure readmission or death.
- Cardiologist Salaries Rise: AMGA’s 189k-provider 2024 salary survey is out, revealing a 4.3% increase among all physicians, and solid raises across cardiology subspecialties. While general cardiologists saw their median compensation increase by 7.9% to $596k, the survey also revealed healthy increases among echocardiologists (12.4%), cardiovascular surgeons (+10.5%), interventional cardiologists (+9.7%), EPs (+8.2%), and pediatric cardiologists (+5.7%). Despite the shortage of advanced heart failure specialists, their median compensation only increased by 2.9%.
|
|
Making the Leap to Outsource Post-Processing
Interested in how to outsource cardiac image post-processing, but not sure where to start? PIA walks you through how to assess and compare vendors, understand pricing models and payment options, and outline your requirements to identify vendors who meet your clinical needs.
|
|
Reducing ECG Background Noise
Monebo’s Kinitec Rhythms ECG Algorithm separates true ECG signals from background noise, leading to more accurate diagnoses and improved operator efficiency. See for yourself how the algorithm measured up to a gold standard.
|
|
Uncover the Brain-Heart Connection
AI might be poised to transform cryptogenic stroke care, but many cardiologists and neurologists still have a lot to learn. Tune-in to this upcoming webinar on July 24th, where Drs. Brett Meyer and Jonathan Hsu will explore how Viz.ai’s post-acute workflow solution, Viz Connect, is being used to accelerate cryptogenic stroke diagnosis and treatment.
|
|
- Catch up on 2024’s Cardiology Coffee Breaks: Join GE HealthCare on a journey to bridge the gaps to connected cardiovascular care with this season’s Cardiology Coffee Breaks. In the time it takes you to finish your coffee, these Coffee Breaks demonstrate how GE’s integrated solutions empower healthcare organizations to provide precision care, achieve operational efficiency, and enhance patient satisfaction.
- The Bunkerhill Blueprint: Advancing an AI solution from concept to clinic used to take years, but Bunkerhill Health is closing that gap at lightning speed. See how Bunkerhill is streamlining AI training, validation, approval, and commercialization to get better AI tools into clinical practice, faster.
- Diagnosis Beyond the Hospital: It’s increasingly clear that healthcare is expanding beyond hospital walls, and recent evidence from Us2.ai suggests that AI-enabled cardiac ultrasound could help drive that expansion. Read these editorials by Izabella Uchmanowicz, RN, PhD and Prof. Blanche J Cupido, MBChB to see how Us2.ai-enabled and nurse-operated mobile ultrasound might both improve and expand heart failure diagnosis.
- Advance Your Cardiac MR Visualization: Ready to advance your CMRI assessments? See how you could leverage TeraRecon’s Intuition Cardiac MR package for a range of cardiac anatomy and physiology evaluations, and how your peers are already benefiting from it.
- Merge Cardiology is Best in KLAS: Merge Cardio and Merge Hemo continued their KLAS hot streak, ranking Best in KLAS 2024 for Cardiology and Hemodynamics for the 9th and 12th years. The Merge by Merative cardiology solutions further expanded their KLAS score leads this year, with Merge Cardio scoring 82.8 (up from 82.7 last year) and Merge Hemo surging to 91.5 (from 85.7 in 2023).
- It’s Time to See The Full Picture: See how HeartFlow ONE is transforming precision heart care as the first all-in-one CCTA pathway, combining FFRCT, stenosis, and plaque analysis in a single workflow.
|
|
|
|
|
